Faculty Bios

Chairperson

Harry P. Erba, MD, PhD 
Professor of Internal Medicine 
Director of the Hematologic Malignancy Program 
University of Alabama at Birmingham 
Birmingham, Alabama 

Dr. Harry P. Erba earned a bachelor’s degree in biology from Yale University, New Haven, Connecticutt, and his Doctor of Medicine and doctorate degrees from Stanford University, Palo Alto, California. He did his internship and residency in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School in Boston. Following a fellowship in hematology/oncology at the same  institution, he joined the Harvard Medical School faculty for 3 years until he moved to the University of Michigan at Ann Arbor in July, 1996, where he rose to the position of Associate Professor of Internal Medicine. In July 2012, he relocated to the University of Alabama at Birmingham as Professor of Internal Medicine. He serves as the Director of the Hematologic Malignancy Program and the Associate Director for Clinical Research in the Comprehensive Cancer Center. He has been an active member in the SWOG Leukemia Committee for over a decade. In October 2012, he was appointed Chairman of the SWOG Leukemia Committee and now serves on the NCI Leukemia Steering Committee. 

Dr. Erba has focused on the assessment of novel therapies in acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndromes. He has been involved in numerous clinical trials in these hematologic malignancies, led many national trials as a chair or co-chair, and played major roles in the development of several new drugs. He was an executive officer of Southwest Oncology  Group, and has served on the National Comprehensive Cancer Network Practice Guidelines Committees for acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and myeloid growth factors. In addition to 47 peer-reviewed publications in Nature, Cell, Journal of Clinical Oncology, Blood, Cancer Research, the British Journal of Haematology, and others. Dr. Erba has authored five book chapters and has lectured extensively in the United States, Canada, South America, Europe, and Japan. 

DISCLOSURE OF CONFLICTS OF INTEREST 

Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships. The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant: 

Harry P. Erba, MD, PhD, reported a financial interest/relationship or affiliation in the form of: grants/research funding, Amgen, Inc., Astellas, Celator Pharmaceuticals, Millennium Pharmaceuticals, Inc., and Seattle Genetics, Inc.; consultant, Amgen, Inc., Celgene, Incyte Corporation, Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc.; speaker’s bureau, Incyte Corporation and Novartis Pharmaceuticals Corporation. 

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Linda Gracie-King, MS, Deborah Middleton, MS, and Tim DiChiara, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 


Faculty

Elihu H. Estey, MD
Professor, Division of Hematology
Director of AML Clinical Research (non-transplant)
University of Washington School of Medicine
Seattle Cancer Care Alliance
Seattle, Washington

Dr. Eilhu Estey is Professor of Medicine in the Division of Hematology at the University of Washington School of Medicine, Director of acute myeloid leukemia (AML) Clinical Research (nontransplant) at the Fred Hutchinson Cancer Research Center, and an attending physician at the Seattle Cancer Care Alliance. 

After earning his doctor of medicine degree from Johns Hopkins University, Dr. Estey completed an internship and residencies in medicine and neurology at New York University in New York City and Bellevue Medical Center in Nebraska and was a fellow in the Department of Developmental Therapeutics at the University of Texas, MD Anderson Cancer Center in Houston. 

Dr. Estey is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society of Cancer Research. His research has focused on clinical trials in AML, particularly those involving new research designs and overall management of patients with AML. An active researcher, Dr. Estey has authored books, more than 400 articles, and abstracts. 

Dr. Estey is on the editorial board of the Journal of Clinical Oncology. He also reviews abstracts for the American Society of Hematology and has reviewed manuscripts for numerous professional publications, including The New England Journal of Medicine, American Journal of Hematology, Leukemia & Lymphoma, and Clinical Cancer Research. He is chairman and member of numerous national committees and has recently been appointed advisor to the Oncology Drugs Advisory Committee for AML Studies of the US Food and Drug Administration. He lectures widely to professional audiences both domestic and abroad. 

DISCLOSURE OF CONFLICTS OF INTEREST

Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships. The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant: 

Harry P. Erba, MD, PhD, reported a financial interest/relationship or affiliation in the form of: grants/research funding, Amgen, Inc., Astellas, Celator Pharmaceuticals, Millennium Pharmaceuticals, Inc., and Seattle Genetics, Inc.; consultant, Amgen, Inc., Celgene, Incyte Corporation, Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc.; speaker’s bureau, Incyte Corporation and Novartis Pharmaceuticals Corporation. 

Elihu H. Estey, MD, has no conflicts of interest to report. 

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Linda Gracie-King, MS, Deborah Middleton, MS, and Tim DiChiara, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


James M. Foran, MD, FRCPC
Associate Professor of Medicine
Vice Chair – Clinical Research
Mayo Clinic Cancer Center
Mayo Clinic Florida
Jacksonville, Florida

Dr. James Foran leads efforts in malignant hematology at Mayo Clinic Florida (Jacksonville), and in the Mayo Clinic Cancer Center with a focus on clinical investigation of novel agents in acute leukemia, health-care disparities, as well as lymphoma and leukemia epidemiology. He serves on the ECOG Leukemia Core Committee and is a member of the InterLymph Epidemiology Consortium. He is currently the principal investigator and National Study Chair of ECOG E2906, the largest phase 3 trial currently being conducted in the United States in newly diagnosed elderly acute myeloid leukemia, studying a lower intensity induction regimen, the role of allogeneic bone marrow transplantation, and maintenance therapy in older patients. 

Dr. Foran is active in education and clinical research nationally and through the American Society of Hematology and American Society of Clinical Oncology, including currently serving on the program committee. He has published more than 50 peer-reviewed manuscripts and textbook chapters in leukemia, myelodysplastic syndrome, and lymphoma. He received his doctor of medicine degree from the University of Manitoba, Canada, and completed his internal medicine residency and medical oncology fellowship in Boston, Massachusetts, at the Beth Israel Hospital and Dana-Farber Cancer Institute, respectively. 

DISCLOSURE OF CONFLICTS OF INTERESTsT 

Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships. The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant: 

Harry P. Erba, MD, PhD, reported a financial interest/relationship or affiliation in the form of: grants/research funding, Amgen, Inc., Astellas, Celator Pharmaceuticals, Millennium Pharmaceuticals, Inc., and Seattle Genetics, Inc.; consultant, Amgen, Inc., Celgene, Incyte Corporation, Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc.; speaker’s bureau, Incyte Corporation and Novartis Pharmaceuticals Corporation. 

James M. Foran, MD, FRCPC, reported a financial interest/relationship or affiliation in the form of: consulting fee, Ariad Pharmaceuticals, Inc. 

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Linda Gracie-King, MS, Deborah Middleton, MS, and Tim DiChiara, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 


Daniel A. Pollyea, MD, MS
Assistant Professor
Clinical Director of Leukemia Services
University of Colorado School of Medicine
Aurora, Colorado

Dr. Daniel A. Pollyea is currently an Assistant Professor and the Clinical Director of Leukemia Services at the University of Colorado School of Medicine in Aurora. He has served as principal investigator of multiple early phase clinical trials and has received funding for his work from the American Society of Hematology, the American Society of Clinical Oncology, and the Leukemia and Lymphoma Society. His research interests involve developmental therapeutics for leukemia and other blood cancers through collaborative laboratory-based efforts and clinical trials involving novel therapies that he designs and leads. He is interested in developing drugs that target leukemia stem cells that will allow for definitive and curative therapies. His research has applications for acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasms (including chronic myeloid leukemia), as well as chronic lymphocytic leukemia. 

Dr. Pollyea received his doctor of medicine degree from the University of Chicago Pritzker School of Medicine in Illinois. He remained at the University of Chicago Hospital for his residency in internal medicine and served as chief medical resident at Cook County Hospital, Chicago, Illinois. He then completed his fellowship training in hematology and oncology at Stanford University in Palo Alto, California, where he also completed a Master of Science in Epidemiology with an emphasis on biostatistics and clinical trial design. 

DISCLOSURE OF CONFLICTS OF INTEREST

Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships. The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant: 

Harry P. Erba, MD, PhD, reported a financial interest/relationship or affiliation in the form of: grants/research funding, Amgen, Inc., Astellas, Celator Pharmaceuticals, Millennium Pharmaceuticals, Inc., and Seattle Genetics, Inc.; consultant, Amgen, Inc., Celgene, Incyte Corporation, Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc.; speaker’s bureau, Incyte Corporation and Novartis Pharmaceuticals Corporation. 

Daniel A. Pollyea, MD, MS, reported a financial interest/relationship or affiliation in the form of: consulting fee, Agios Pharmaceuticals and Celgene Corporation. 

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Linda Gracie-King, MS, Deborah Middleton, MS, and Tim DiChiara, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 


Gail J. Roboz, MD 
Associate Professor of Medicine 
Director of the Clinical and Translational Leukemia Programs 
Weill Medical College of Cornell University 
New York-Presbyterian Hospital 
New York, New York

Gail Roboz, MD, is Associate Professor of Medicine and Director of the Clinical and Translational Leukemia Programs at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York, New York. Her research focuses on developmental therapeutics for acute leukemia, myelodysplastic syndrome, and myeloproliferative disorders. Dr. Roboz is a principal investigator on several clinical trials and has authored and coauthored many manuscripts and abstracts on these malignancies. 

Dr. Roboz is on the editorial board of and serves as a reviewer for several journals, and has played an active role as a speaker and panelist at numerous regional, national, and international conferences. She is a member of the American Society of Hematology and the American Society of Clinical Oncology. Dr. Roboz also serves on the Medical Advisory Board of the Aplastic Anemia and MDS International Foundation. She received her Doctor of Medicine degree from Icahn School of Medicine at Mount Sinai in New York, New York. 

DISCLOSURE OF CONFLICTS OF INTEREST 

Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships. The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant: 

Harry P. Erba, MD, PhD, reported a financial interest/relationship or affiliation in the form of: grants/research funding, Amgen, Inc., Astellas, Celator Pharmaceuticals, Millennium Pharmaceuticals, Inc., and Seattle Genetics, Inc.; consultant, Amgen, Inc., Celgene, Incyte Corporation, Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc.; speaker’s bureau, Incyte Corporation and Novartis Pharmaceuticals Corporation. 

Gail J. Roboz, MD, reported a financial interest/relationship or affiliation in the form of: advisory board, Astex Pharmaceuticals Inc., Boehringer Ingelheim, Celgene Corporation, Novartis Pharmaceuticals Corporation, Roche USA, Seattle Genetics, Inc., and Teva Pharmaceuticals; consulting fee, Agios Pharmaceuticals, Inc. 

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Linda Gracie-King, MS, Deborah Middleton, MS, and Tim DiChiara, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 


Mikkael A. Sekeres, MD, MS
Professor of Medicine
Director of the Leukemia Program
Vice Chair for Clinical Research
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Dr. Mikkael A. Sekeres is the Professor of Medicine, Director of the Leukemia Program, and Vice Chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio. He earned a doctor of medicine degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine in Philadelphia. Dr. Sekeres completed his postgraduate training at Harvard University in Cambridge, Massachusetts, finishing an internal medicine residency at Massachusetts General Hospital and a fellowship in hematology-oncology at the Dana-Farber Cancer Institute in Boston. 

Dr. Sekeres is chairman of the Oncologic Drugs Advisory Committee of the US Food and Drug Administration and is co-chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndrome International Foundation. An invited speaker at numerous meetings, grand rounds, and conferences, Dr. Sekeres is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the Southwest Oncology Group—Leukemia Committee. His current research focuses on patients with myelodysplastic syndrome and older adults with acute myeloid leukemia, and he is national primary study investigator on several phase 1 and 2 clinical trials. He is the author or coauthor of over 220 articles and over 250 abstracts published in leading journals such as Blood, Journal of Clinical Oncology, Nature Genetics, Journal of the National Cancer Institute, PLoS One, Cancer, Haematologica, and Leukemia; the co-author of 5 books; and he is on the editorial board of the Journal of Clinical Oncology, Leukemia, Oncologist, and the Blood Cancer Journal. Additionally, Dr. Sekeres is an essayist for The New York Times and an award-winning columnist and the Clinical Advisory Editor for the Oncology Times. 

DISCLOSURE OF CONFLICTS OF INTEREST 

Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships. The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant: 

Harry P. Erba, MD, PhD, reported a financial interest/relationship or affiliation in the form of: grants/research funding, Amgen, Inc., Astellas, Celator Pharmaceuticals, Millennium Pharmaceuticals, Inc., and Seattle Genetics, Inc.; consultant, Amgen, Inc., Celgene, Incyte Corporation, Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc.; speaker’s bureau, Incyte Corporation and Novartis Pharmaceuticals Corporation. 

Mikkael A. Sekeres, MD, MS, reported a financial interest/relationship or affiliation in the form of: consulting fee, Amgen, Inc. and Celgene Corporation. 

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Linda Gracie-King, MS, Deborah Middleton, MS, and Tim DiChiara, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.